Drugs that contain Dapagliflozin; Metformin Hydrochloride

1. Drug name - XIGDUO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May, 2030

(7 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations Nov, 2030

(8 years from now)

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.